Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study to evaluate triple combination of buntanetap and other drugs, including Trulicity and Viagra to enhance cognitive function

Next Previous
Trial Profile

A phase III study to evaluate triple combination of buntanetap and other drugs, including Trulicity and Viagra to enhance cognitive function

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary) ; Dulaglutide (Primary) ; Sildenafil (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Parkinson's disease
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Apr 2026 According to Annovis Bio media release, company announced $10 Million underwritten Offering of Common Stock.Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimers disease.
  • 13 Oct 2024 New trial record
  • 03 Oct 2024 According to Annovis Bio media release, the company has secured intellectual property for innovative combination therapy involving buntanetap and other drugs, including Trulicity and Viagra.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top